Summit Therapeutics (SMMT) EBIAT (2016 - 2026)
Summit Therapeutics filings provide 13 years of EBIAT readings, the most recent being -$189.4 million for Q1 2026.
- Quarterly EBIAT fell 201.09% to -$189.4 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$1.2 billion through Mar 2026, down 400.96% year-over-year, with the annual reading at -$1.1 billion for FY2025, 387.81% down from the prior year.
- EBIAT hit -$189.4 million in Q1 2026 for Summit Therapeutics, up from -$219.2 million in the prior quarter.
- Across five years, EBIAT topped out at -$14.7 million in Q2 2023 and bottomed at -$565.7 million in Q2 2025.
- Average EBIAT over 5 years is -$128.5 million, with a median of -$56.3 million recorded in 2024.
- The largest annual shift saw EBIAT tumbled 2434.82% in 2023 before it skyrocketed 91.98% in 2024.
- Summit Therapeutics' EBIAT stood at -$19.2 million in 2022, then crashed by 90.17% to -$36.6 million in 2023, then crashed by 67.37% to -$61.2 million in 2024, then tumbled by 258.11% to -$219.2 million in 2025, then rose by 13.57% to -$189.4 million in 2026.
- Per Business Quant, the three most recent readings for SMMT's EBIAT are -$189.4 million (Q1 2026), -$219.2 million (Q4 2025), and -$231.8 million (Q3 2025).